Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 10Gliosarcoma 8Glioblastoma 8Brain Neoplasms 7Rhabdomyosarcoma 4Osteosarcoma 4Oligodendroglioma 4Glioma 4Astrocytoma 4Central Nervous System Neoplasms 3Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Liposarcoma 2Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Recurrent Uterine Sarcoma 1Recurrence 1Pinealoma 1Pharyngeal Neoplasms 1Neurofibrosarcoma 1Neurofibromatosis 2 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Mesothelial 1Neoplasms 1

Interventions

temsirolimus 1linrodostat 1ixabepilone 1Taxes 1Sunitinib 1Sirolimus 1Paclitaxel 1Nivolumab 1Laparoscopy 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × temsirolimus × Sarcoma × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡